Stability of VIII:C in plasma: the dependence on protease activity and calcium.
Loss of Factor VIII procoagulant activity (VIII:C) following blood collection is a major problem in providing sufficient amounts for therapeutic use and biochemical analyses. We have examined the effects of inhibition of plasma proteases and maintenance of physiological calcium ion on plasma VIII:C stability. The addition of protease inhibitors such as benzamidine, phenylmethylsulfonyl fluoride (PMSF), aprotinin, or soybean trypsin inhibitor (SBTI) to CPD plasma provided no significant protection against decay of VIII:C activity. Neither the rate of decay in the first 24 hours nor the final VIII:C activity observed after storage for 48-72 hours were significantly altered. On the other hand, addition of DFP or heparin to CPD plasma resulted in a marked improvement in VIII:C stability over 24 hours. This demonstrated that these two inhibitors are effective in preventing VIII:C degradation during storage. In addition to protease inhibition, the importance of maintaining physiological calcium ion was demonstrated by 100% stabilization of VIII:C in heparin plasma. Plasma obtained from CPD plus heparin blood could also be stabilized provided free calcium ion levels were restored to physiological concentrations. The inactivation of VIII:C in CPD plus heparin plasma was completely reversible up to 4 hours after collection. Studies on the recovery of activity after recalcification of CPD plus heparin plasma provided kinetic data which support a renaturation process of VIII:C rather than one due to enzymatic activation. The use of a thrombin-specific chromogenic substrate revealed that after recalcification and during the recovery of VIII:C activity, there was no significant thrombin activity. Although the data suggest that proteolytic degradation plays some part in VIII:C decay, only the maintenance of physiologic calcium ion levels under cover of an effective non-chelating anticoagulant and protease inhibitor allows preservation of VIII:C activity.
D000925:Anticoagulants / Q000494:pharmacology; D000941:Antigens / Q000032:analysis*; D001550:Benzamidines / Q000494:pharmacology; D001793:Blood Preservation; D002118:Calcium / Q000494:pharmacology*; D002614:Chelating Agents / Q000494:pharmacology; D005169:Factor VIII / Q000032:analysis / Q000276:immunology*; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007531:Isoflurophate / Q000494:pharmacology; D008297:Male; D010664:Phenylmethylsulfonyl Fluoride / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D013048:Specimen Handling; D013917:Thrombin / Q000494:pharmacology
D000925:Anticoagulants; D000941:Antigens; D001550:Benzamidines; D002614:Chelating Agents; D011480:Protease Inhibitors; D007531:Isoflurophate; D010664:Phenylmethylsulfonyl Fluoride; D005169:Factor VIII; D006493:Heparin; D013917:Thrombin; C032157:benzamidine; D002118:Calcium